Groundbreaking immune therapy trial opens for advanced cancer patients
NCT ID NCT06952010
Summary
This is the first human study of a new experimental drug called XB628, designed to help the immune system fight cancer. The trial will test different doses of the drug in 75 people with advanced solid tumors that have returned or spread after previous treatments. The main goals are to find a safe dose and see how the body processes the drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Exelixis Clinical Site #1
RECRUITINGHickory, North Carolina, 28602, United States
-
Exelixis Clinical Site #10
RECRUITINGBoston, Massachusetts, 02114, United States
-
Exelixis Clinical Site #2
RECRUITINGSan Antonio, Texas, 78229, United States
-
Exelixis Clinical Site #3
RECRUITINGNashville, Tennessee, 37203, United States
-
Exelixis Clinical Site #8
RECRUITINGTampa, Florida, 33612, United States
-
Exelixis Clinical Site #9
RECRUITINGHouston, Texas, 77030, United States
-
Exelixis Site #4
RECRUITINGNew Haven, Connecticut, 06520, United States
-
Exelixis Site #5
RECRUITINGSan Francisco, California, 94158, United States
-
Exelixis Site #6
RECRUITINGSt Louis, Missouri, 63108, United States
-
Exelixis Site #7
RECRUITINGNew York, New York, 10029, United States
Conditions
Explore the condition pages connected to this study.